The effect of intravenous iron on fgf23 and iron profile

The effect of injectable iron supplementation on FGF23 levels in hemodialysis patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190506043488N1

Enrollment

Registered

2019-12-27

Start date

2019-09-23

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron deficiency anemia in hemodialysis patients. Chronic kidney disease, stage 5

Interventions

Intervention group: Hemodialysis patients who meet the inclusion criteria will receive 100 mg of intravenous iron (venoffer) supplement 10 times during 3 months after each dialysis..

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All patients with hemodialysis who have completed their dialysis for at least 3 months. All patients with hemodialysis aged 18 to 70 years. All patients with hemodialysis have ferritin less than 200 and transferin saturation less than 20 %.

Exclusion criteria

Exclusion criteria: Dissatisfaction patients to enter the study transfusion Malignancy Parathyroidectomy Infection of any type ( catheter infection, UTI,....) Recent consumption of corticosteroid Active bleeding Advanced heart disease liver disease

Design outcomes

Primary

Measure	Time frame
Fibroblast growth factor 23 level. Timepoint: Measurement of Fibroblast growth factor 23 level at the beginning of the study (before intervention) and 3 months after intervention. Method of measurement: Laboratory measurement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactForoogh Asli

Zahedan University of Medical Sciences

forooghasli1366@zaums.ac.ir+98 54 3329 5575

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026